A choice of optimal regimen for cicposporine-therapy in recipients of allogenic kidneys at different peropds after the operation
Abstract
To evaluate an adequacy of Cyclosporine-therapy in 54 recipients of allogenic kidneys (28 males and 26 females aged 6-49 years) were examined T-0, T-1, T-3 with AUC (area under the curve) calculation. All the patients were from 3 to 3056 days after the operation. All received data were exposed to statistic analysis with determination of a correlation degree. A mathematic analysis revealed that a correlation between CyA-dose and these parameters is very various (r = 0.2878-0.5765). CyA-dose most closely correlated with T-3 and AUC (r = 0.5554-0.5765). Therefore, for correcting CyA-dose we should be oriented on T-3 and AUC.
About the Authors
M. M. Kaabak
Отдел трансплантации органов, Лаборатория клинической иммунологии Российского Научного Центра Хирургии РАМН
Russian Federation
Russian Federation
V. A. Goriainov
Отдел трансплантации органов, Лаборатория клинической иммунологии Российского Научного Центра Хирургии РАМН
Russian Federation
Russian Federation
L. I. Agureeva
Отдел трансплантации органов, Лаборатория клинической иммунологии Российского Научного Центра Хирургии РАМН
Russian Federation
Russian Federation
L. I. Vinnitsky
Отдел трансплантации органов, Лаборатория клинической иммунологии Российского Научного Центра Хирургии РАМН
Russian Federation
Russian Federation
N. T. Vorobieva
Отдел трансплантации органов, Лаборатория клинической иммунологии Российского Научного Центра Хирургии РАМН
Russian Federation
Russian Federation
References
1. Kahan B.D. Cyclosporine. N. Engl. J. Med., 1989, 321, 1725-1738.
2. The Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: Analysis at three years. N. Engl. J. Med.,1986, 314, 1219-1225.
3. Starzl T.E., Klintmalm G.B.D., Porter K.A. et al. Liver transplantation with use of cyclosporin A and prednisone. N. Engl. J. Med., 1981, 305, 266-269.
4. Macoviak J.A., Oyer P.E., Stinson E.B. et al. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant. Proc., 1985, 17 (suppl 2): 1985, 97-101.
5. Traeger J., Dubernard J., Pozza G. Influence of immunosuppressive therapy on the endocrine function of segmental pancreatic allografts. Transplant. Proc., 1983, 15. 1326-1329.
6. Myers B.D. Cyclosporine nephrotoxicity. Kidney Int., 1986, 30, 964-974.
7. Klintmalm G.B.D., Sawe J., Ringden O. et al. Cyclosporine plasma levels in renal transplant patients: Association with renal toxicity and allograft rejection. Transplantation, 1985, 39, 132-137.
8. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin. Pharmacol. Ther., 1993, 54, 205-218.
9. Grevel J., Welsh M.S., Kahan B.D. Cyclosporine monitoring in renal transplantation: Area under the curve is superior to trough level monitoring. Ther. Drug Monit., 1989, 11, 246-248.
10. Gaspari F., Ruggementi P., Torre L. et al. Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Int.,1993, 44, 436-439.
11. Gaspari F., Anedda M.F., Signorini O. et al. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J. Amer. Soc. Nephrol., 1997, 8, 4, 647-652.
Review
For citations:
Kaabak M.M., Goriainov V.A., Agureeva L.I., Vinnitsky L.I., Vorobieva N.T. A choice of optimal regimen for cicposporine-therapy in recipients of allogenic kidneys at different peropds after the operation. Nephrology and Dialysis. 2001;3(1):57-60. (In Russ.)
Views:
10
Email this article 